| Literature DB >> 28577559 |
Jing Wang1, Yubing Wen1, Mengyu Zhou1, Xiaoxiao Shi1, Lanping Jiang1, Mingxi Li1, Yang Yu2,3, Xuemei Li1, Xuewang Li1, Wen Zhang1, Andrew L Lundquist4, Limeng Chen5.
Abstract
BACKGROUND: This study reports the clinical and pathological features of 12 cases of primary Sjogren syndrome (pSS) with renal involvement presenting with proximal tubular dysfunction in a single center, and investigates the possible correlation of ectopic germinal center formation and megalin/cubilin down-expression.Entities:
Keywords: Cubilin; Ectopic germinal center; IL-17; Megalin; Primary Sjogren syndrome
Mesh:
Substances:
Year: 2017 PMID: 28577559 PMCID: PMC5455124 DOI: 10.1186/s13075-017-1317-x
Source DB: PubMed Journal: Arthritis Res Ther ISSN: 1478-6354 Impact factor: 5.156
Comparison of clinical profile between patients with pSS + Fanconi syndrome and pSS + TIN
| pSS with Fanconi syndrome | pSS with TIN |
| |
|---|---|---|---|
| ( | ( | ||
| Age (years) | 39.3 ± 8.6 | 37.6 ± 12.2 | 0.366 |
| Gender (female %) | 10 (83.3) | 18 (90.0) | 0.620 |
| Presenting symptoms | |||
| Polyuria | 8 (66.7) | 10 (50.0) | 0.471 |
| Muscle weakness | 9 (75.0) | 14 (70.0) | 1.000 |
| Nocturia | 7 (58.3) | 5 (25.0) | 0.130 |
| dRTA | 9 (75.0) | 11 (55.0) | 0.452 |
| Paralysis | 3 (25.0) | 6 (30.0) | 1.000 |
| SCr elevation | 9 (75.0) | 12 (60.0) | 0.465 |
| eGFR (ml/min/1.73 m2) | 66.08 ± 38.20 | 76.14 ± 39.57 | 0.716 |
| Serum potassium (mmol/L) | 2.79 ± 0.14 | 2.76 ± 0.24 | 0.120 |
| Serum calcium (mmol/L) | 2.23 ± 0.14 | 2.13 ± 0.09 | 0.104 |
| Serum phosphorus (mmol/L) | 0.69 ± 0.33 | 1.02 ± 0.29 | 0.001 |
| 24-h urine protein (g/24 h) | 1.51 ± 0.84 | 1.00 ± 0.61 | 0.019 |
| Systemic manifestations | |||
| ESSDAI | 18.83 ± 7.83 | 15.50 ± 6.53 | 0.289 |
| Weight loss (>5%) | 7 (58.3) | 6 (30.0) | 0.150 |
| Glandular | 2 (16.7) | 3 (15.0) | 1.000 |
| Cutaneous | 1 (8.3) | 1 (5.0) | 1.000 |
| Pulmonary | 1 (8.3) | 3 (15.0) | 1.000 |
| Lymphadenopathy | 0 (0.0) | 2 (10.0) | 0.516 |
| HGB (g/L) | 105.3 ± 25.2 | 113.4 ± 13.6 | 0.408 |
| Immune profile | |||
| ESR (mm/h) | 58.8 ± 30.9 | 42.7 ± 30.9 | 0.141 |
| ANA positive | 9 (75.0) | 18 (90.0) | 0.338 |
| SSA positive | 5 (41.7) | 14 (73.7) | 0.130 |
| SSB positive | 3 (25.0) | 19 (47.1) | 0.273 |
| IgG (g/L) | 18.3 ± 8.2 | 19.7 ± 6.3 | 0.588 |
Data presented as number (%) or mean ± SD unless otherwise noted
ANA antinuclear antibody, dRTA distal renal tubule acidosis, eGFR estimated glomerular filtration rate, ESR erythrocyte sedimentation rate, ESSDAI Eular Sjogren’s Syndrome Disease Activity Index, HGB hemoglobin, IgG immunoglobulin G, pSS primary Sjogren syndrome, SCr serum creatinine, SSA Sjogren-syndrome-related antigen A, SSB Sjogren-syndrome-related antigen B, TIN tubulointerstitial nephritis
*Mann–Whitney (two-tailed) test for continuous variables and Fisher’s exact (two-tailed) test for categorical variables
Fig. 1Patients with pSS + Fanconi syndrome show remarkable pathological lesions of renal proximal tubule. a Masson staining reveals interstitial fibrosis. b Boxed area in a enlarged. c Hematoxylin and eosin E staining indicating focus of lymphocyte infiltration. d Boxed area in c enlarged, indicating plasma cells in lymphocytes focus
Fig. 2Immunohistochemistry and immunofluorescence reveals loss of megalin and cubilin expression in pSS patients with Fanconi syndrome. Staining of megalin (A, C) and cubilin (B) on kidney biopsies of patients with glomerular minor lesion (GML) (Aa, Ba, Ca), patients of pSS with tubulointerstitial nephritis (Ab, Bb), and pSS patients with Fanconi syndrome (Ac, Bc, Cb). Semiquantitative analysis shows decreased expression of megalin (D) and cubilin (E) in pSS patients with Fanconi syndrome, compared with GML and SS + TIN groups. GML glomerular minor lesion, SS Sjogren syndrome, TIN tubulointerstitial nephritis
Fig. 3EGC of pSS with Fanconi syndrome. Immunohistochemical staining for CD21 in the kidney cortex (a, b) (boxed area in a is enlarged in b: a × 40, b × 200). Classification of lymphocytes aggregating in the proximal tubule: c G1, d G2 and e G3
Fig. 4Expression of IL-17A and megalin in serial sections. Immunohistochemical staining of IL-17A (a) and megalin (b) on adjacent kidney paraffin sections from a patient with pSS + Fanconi syndrome. Proximal tubules with high expression of IL-17A show loss of megalin (asterisks), and those with preserved megalin expression have no IL-17A staining (arrow). c, d Identification of IL-17A expressing cells (arrow) in renal interstitium with hematoxylin staining of nucleus
Comparison of clinical profile between our cases and pSS-related Fanconi syndrome reported in the literature
| Reference | Presenting symptoms | RTA | Cr | K (mmol/L) | Histology | Treatment | Outcome |
|---|---|---|---|---|---|---|---|
| Shearn and Tu [ | Polyuria | + | n.a. | 3.8 | TIN, tubular atrophy | n.a. | n.a. |
| Walker et al. [ | Paralysis, polyuria | + | n.a. | n.a. | TIN | Prednisolone 10 mg/day | n.a. |
| Kamm and Fischer [ | Polyuria, nocturia, weight loss | + | 2.7 mg/dl | 2.9 | Diffuse TIN | Supportive only | Improved |
| Matsumura et al. [ | n.a. | n.a. | 2.7 mg/dl | n.a. | TIN, tubulitis | n.a. | n.a. |
| Ardiles et al. [ | Muscle weakness | + | 1.3 mg/dl | 2.5 | n.a. | Prednisolone “low dose” | Improved |
| Bridoux et al. [ | Weight loss | + | 1.8 mg/dl | 3.5 | Diffuse TIN, proximal tubulitis | Supportive only | Dieda |
| Polyuria | + | 1.6 mg/dl | 2.4 | Diffuse TIN, proximal tubulitis | Prednisolone 10 mg/day | Improved | |
| Kobayashi et al. [ | Muscle weakness | + | 1.3 mg/dl | 2.7 | Diffuse TIN, proximal tubule atrophy | Prednisolone 30 mg/day, 6 months later 12.5 mg/day | Improved |
| Ren et al. [ | n.a. | ||||||
| Yang et al. [ | Muscle weakness, respiratory distress | + | 1.4 mg/dl | 2.7 | n.a. | Supportive only | n.a. |
| Nakamura et al. [ | Renal dysfunction, organizing pneumonia, multiple bone fracture | + | 1.3 mg/dl | 3.0 | n.a. | Mizoribine 50 mg/day | n.a. |
| Wang et al. [ | Hypokalemic paralysis | + | 2.2 mg/dl | 1.6 | Diffuse TIN | Mycophenolate mofetil 1 g/day | Improvedf |
| Ram et al. [ | Paralysis | + | 2.1 mg/dl | 1.3 | Dense lymphocytic interstitial infiltrate | Supportive only | Improved |
| Celik et al. [ | Paralysis, cardiac arrestc | + | 1.1 mg/dl | 1.1 | n.a. | Prednisone 40 mg/d iv. in acute phase | Improvedf |
| Shi and Chen [ | Proteinuria, glycosuriad | + | 3.07 | TIN | Methylprednisolone | Improvede | |
| Saeki et al. [ | Renal dysfunction | + | 1.07 mg/dl | 3.7 | TIN | Prednisolone 40 mg/day | Improvede |
| Kong et al. [ | Weakness, osteodynia, impaired mobility | _ | n.a. | 1.3 | n.a. | Prednisone 30 mg/day | |
| Our cases | Fatigue, anorexia | + | 151 μmol/L | 3.4 | Diffuse TIN, diffuse tubule atrophy, lymphocyte infiltration | Prednisone 50 mg/day | Improvedf |
| Fatigue, polyuria, anorexia, osteopathy | + | 88 μmol/L | 2.1 | Focal TIN, focal tubule atrophy | Prednisone 40 mg/day | Improvedf | |
| Fatigue, anorexia, osteopathy | + | 176 μmol/L | 3.3 | Diffuse TIN, diffuse tubule atrophy, lymphocyte infiltration | Prednisone 50 mg/day | Improvede | |
| Fatigue, anorexia | + | 305 μmol/L | 2.7 | Focal TIN, focal tubule atrophy | Prednisone 45 mg/day | Improvede | |
| Fatigue, anorexia, polyuria | – | 72 μmol/L | 2.53 | Mild tubulitis | Supportive only | Improvedf | |
| Fatigue, anorexia, polyuria | + | 184 μmol/L | 3.0 | n.a. | Prednisone 35 mg + cyclophosphamide 0.2 g qod | Improvede | |
| Polyuria | – | 120 μmol/L | 3.4 | n.a. | Prednisone 60 mg/day | Improvede | |
| Fatigue, polyuria, anorexia, osteopathy | + | 202 μmol/L | 2.62 | n.a. | Prednisone 55 mg/day | Improvede | |
| Osteopathy | – | 110 μmol/L | 3.2 | n.a. | Prednisone 55 mg/day + metrotraxate 10 mg qw | Improvedf | |
| Fatigue, polyuria, osteopathy | + | 75 μmol/L | 2.88 | n.a. | Prednisone 40 mg/day + cyclophosphamide 0.2 g qod | Improvedf | |
| Hypokalemic paralysis, osteopathy | + | 65 μmol/L | 2.1 | n.a. | Supportive | Improvedf | |
| polyuria, osteopathy | + | 71 μmol/L | 2.34 | n.a. | Prednisone 30 mg/day + metrotraxate 10 mg qw | Improvedf | |
Mean age of patients with pSS-related Fanconi syndrome reported in the literature is 47.4 ± 13.2, with a female ratio of 93.3%
n.a. not available, pSS primary Sjogren syndrome, qop every other day, qw every week, RTA renal tubule acidosis, TIN tubulointerstitial nephritis
aProbable cardiovascular event
bFour cases reported in a retrospective study of 130 cases, no detailed information
cAlso diagnosed of brucellic disease
dWith autoimmune thyroiditis
eImprovement of renal function, and stable during follow-up
fCorrection of electrolyte derangement, and relief of symptoms